Abciximab - Biologic Drug Details

Summary for abciximab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for abciximab

Recent Clinical Trials for abciximab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Baylor College of Medicine	Phase 1/Phase 2
Assiut University	Phase 1/Phase 2
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4

See all abciximab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for abciximab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for abciximab Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for abciximab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Abciximab

Last updated: March 31, 2026

What is Abciximab?

Abciximab is a glycoprotein IIb/IIIa receptor antagonist used primarily during percutaneous coronary interventions (PCI) to prevent thrombotic complications. It blocks platelet aggregation, reducing the risk of myocardial infarction and other ischemic events during coronary procedures. Approved by the FDA in 1994, it remains a key anticoagulant agent in interventional cardiology.

Market Adoption and Usage Trends

Cardiology Procedures

Abciximab's clinical use is concentrated in PCI, including:

• Angioplasty
• Stent placement
• Coronary artery bypass grafting (off-label)

Data indicates that its use has declined over the past decade, primarily replaced by newer agents with improved safety profiles.

Competition Landscape

Abciximab faces competition from:

• Eptifibatide (Integrilin): FDA approved in 1998, more selective, with a shorter half-life.
• Tirofiban (Aggrastat): FDA approved in 1998, oral administration available in some contexts.
• Newer agents and oral anticoagulants: Increasing adoption reduces reliance on abciximab in certain indications.

Market Penetration and Regional Variations

• North America: Dominates initial usage, though decline is evident in recent years
• Europe: Similar trend, with some countries favoring newer agents
• Asia-Pacific: Growing adoption in certain markets, influenced by local clinical guidelines

Regulatory and Reimbursement Environment

Regulatory Status

• FDA: Approved since 1994
• EMA: Approved in Europe, with some restrictions based on risk-benefit assessments

Reimbursement Policies

Reimbursement is tied to procedural indications. Payers increasingly prefer agents with lower bleeding risks and simplified dosing, impacting abciximab’s market share.

Financial Trajectory and Sales Data

Historical Sales

From $450 million in 2010, annual sales declined to approximately $150 million in 2022, reflecting reduced clinical adoption [1].

Key Market Factors

• Patent Status: Abciximab's patent expired in 2005, allowing biosimilars and generics to enter the market, lowering costs.
• Manufacturing Costs: Impacted by biosimilar competition, reducing profit margins.
• R&D Investment: No recent significant R&D efforts targeting abciximab, shifting focus away from this agent.

Future Revenue Projections

• Expected decline at an average compound annual rate of approximately 10-15% over the next five years.
• Market consolidation reduces competition, but newer agents further diminish abciximab's relevance.

Clinical and Market Impact of Newer Agents

• Clinicians favor eptifibatide and tirofiban due to shorter infusion times and better safety profiles.
• Oral anticoagulants (e.g., rivaroxaban, apixaban) are used off-label in some scenarios, further limiting abciximab's role.
• Cost-effectiveness analyses favor newer agents that reduce bleeding complications and hospital stay durations.

Key Challenges and Opportunities

Challenges

• Shrinking market size
• Competition from oral anticoagulants and other GP IIb/IIIa inhibitors
• Safety concerns, notably bleeding risks

Opportunities

• Niche applications in specific interventional procedures
• Combination therapy protocols
• Development of next-generation biologics with improved safety

Summary Statistics

Indicator	2010	2022	Projected 2027
Global sales (USD million)	450	150	80-100
Market share (interventional use)	~60%	~25-30%	<20%
Patent status	Expired in 2005	–	–

Conclusion

Abciximab's market has contracted significantly, driven by the advent of safer, more convenient agents and changing clinical practices. Its revenue trajectory indicates ongoing declines, with limited upside barring new indications or formulations.

Key Takeaways

• Abciximab is mainly used in PCI but faces reduced use due to alternative agents.
• Sales have declined from peak levels of approximately $450 million in 2010 to $150 million in 2022.
• Patent expiration and biosimilar entry have contributed to price decline and market share loss.
• Future revenue will diminish further, guided by evolving clinical preferences and competition.
• Opportunities exist mostly in niche procedural applications or in combination therapy protocols.

FAQs

1. What factors have most contributed to abciximab's sales decline?
The main factors include competition from newer agents with better safety profiles, the expiration of its patent, and shifts in clinical guidelines favoring oral anticoagulants.

2. Are biosimilars impacting abciximab's market share?
Yes. Biosimilar versions introduced post-2005 have reduced costs and increased accessibility, intensifying price competition.

3. Can abciximab regain market relevance?
Unlikely without new formulations or indications. Current trends favor agents with lower bleeding risks and easier administration.

4. How does regional variation affect abciximab adoption?
Usage remains higher in North America but has declined globally, especially in Europe and Asia-Pacific where alternative agents are preferred.

5. What are the prospects for future revenue?
Sales are expected to continue declining at 10-15% annually, with minimal growth outlooks in traditional indications.

---

References

[1] MarketWatch. (2023). Abciximab market data and sales figures. Retrieved from https://www.marketwatch.com